Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O94925
UPID:
GLSK_HUMAN
Alternative names:
K-glutaminase; L-glutamine amidohydrolase
Alternative UPACC:
O94925; Q9UL05; Q9UL06; Q9UL07; Q9UN40
Background:
Glutaminase kidney isoform, mitochondrial, also known as K-glutaminase and L-glutamine amidohydrolase, plays a pivotal role in renal catabolism of glutamine and in maintaining acid-base homeostasis. It regulates neurotransmitter glutamate levels, crucial for brain function.
Therapeutic significance:
Linked to diseases like Developmental and epileptic encephalopathy 71, and others involving glutamate excess and neurodevelopmental issues, understanding Glutaminase kidney isoform's role could lead to novel therapeutic strategies.